2018.Apr.19
FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors
Date of occurrence of the event: April 19, 2018 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: FDA clearance of OBI-3424 IND application for a Phase I/II study targeting AKR1C3 solid tumors Countermeasures: None Any other matters that […]
This article is password protected.
To view the content, please enter your password in the field below